These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070 [TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone: new indication. More risky than beneficial in advanced prostate cancer. Prescrire Int; 2001 Aug; 10(54):110-2. PubMed ID: 11718179 [TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen response to mitoxantrone and prednisone in patients with refractory prostate cancer: prognostic factors and generalizability of a multicenter trial to clinical practice. Dowling AJ; Czaykowski PM; Krahn MD; Moore MJ; Tannock IF J Urol; 2000 May; 163(5):1481-5. PubMed ID: 10751862 [TBL] [Abstract][Full Text] [Related]
13. Cancer and Leukemia Group B trials for advanced prostate cancer. Small EJ; Dawson NA; Kantoff PW; Vogelzang NJ Semin Oncol; 1996 Dec; 23(6 Suppl 14):28-31. PubMed ID: 8996582 [TBL] [Abstract][Full Text] [Related]
14. Management of hormone refractory prostate cancer. Lin AM; Small EJ Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361 [TBL] [Abstract][Full Text] [Related]
15. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902 [TBL] [Abstract][Full Text] [Related]
16. The role of systemic cytotoxic therapy for prostate cancer. Chang SS; Kibel AS BJU Int; 2009 Jan; 103(1):8-17. PubMed ID: 19040524 [TBL] [Abstract][Full Text] [Related]
17. [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer]. Breton X; Lechevallier E; Coulange C Prog Urol; 2005 Jun; 15(3):398-404. PubMed ID: 16097142 [TBL] [Abstract][Full Text] [Related]
18. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?]. El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer. Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757 [TBL] [Abstract][Full Text] [Related]
20. The case for early chemotherapy for the treatment of metastatic disease. Lucas A; Petrylak DP J Urol; 2006 Dec; 176(6 Pt 2):S72-5. PubMed ID: 17084173 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]